In addition, a more recent study showed that blocking the MCP1 (CCL2)-CCR2 interaction with a CCL2-neutralizing antibody in a murine hepatocellular carcinoma model reduced the number of inflammatory myeloid cells (CD11highGr1+) and increased the cytotoxicity of hepatic NK cells [33]. Here, CCL2 is linked to hepatocellular carcinoma.